Chiron/Organon Teknika
This article was originally published in The Gray Sheet
Executive Summary
Firms ink semi-exclusive, worldwide license for patents relating to the development of assays for detection of HIV in nucleic acid sequences in clinical diagnostics, excluding blood screening. Organon is the third licensee of the patents, including Bayer AG and Roche. Chiron will receive royalty payments based on a percentage of net sales of current and future Organon Teknika offerings, subject to minimum royalties as a fixed amount per test sold
You may also be interested in...
BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.